FDA 483 - Lonza Biologics, Inc. - June 06, 2025

Lonza Portsmouth, Inc. was inspected regarding its drug product manufacturing operations for CASGEVY. The inspection revealed significant deficiencies in aseptic processing, facility cleaning, documentation practices, HVAC controls, deviation management, environmental monitoring, and sterility testing. These issues indicate a broad lack of control over critical manufacturing processes and quality systems.